原发性脑胶质瘤的姑息性放疗。
Palliative Radiotherapy of Primary Glioblastoma.
机构信息
Department of Radiation Oncology, University of Lübeck, Lübeck, Germany.
Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, U.S.A.
出版信息
In Vivo. 2021 Jan-Feb;35(1):483-487. doi: 10.21873/invivo.12282.
BACKGROUND/AIM: Care is often palliative when patients are not fit and complete resection of glioblastomas cannot be achieved. This study aimed to identify predictors of survival after palliative radiotherapy.
PATIENTS AND METHODS
Thirty-one patients irradiated after biopsy or incomplete resection of primary glioblastoma were retrospectively analyzed. Median total dose, dose per fraction and equivalent dose in 2 Gy fractions (EQD2) were 45.0 Gy, 3.0 Gy and 46.0 Gy, respectively. Median number of fractions was 15, median treatment time 3 weeks. Ten patients received temozolomide. Six factors were evaluated for survival including location of glioblastoma, Karnofsky performance score (KPS), gender, age, EQD2 and temozolomide.
RESULTS
KPS ≥60 showed a trend for improved survival (p=0.141). For other factors including EQD2, no significant association with survival was found.
CONCLUSION
Patients with a KPS ≤50 have a poor survival prognosis and appear good candidates for short-course radiotherapy. Selected patients with better KPS may be considered for more aggressive treatments.
背景/目的：当患者身体状况不佳且无法完全切除胶质母细胞瘤时，通常采取姑息治疗。本研究旨在确定姑息性放疗后生存的预测因素。
患者和方法
回顾性分析了 31 名经活检或不完全切除原发性胶质母细胞瘤后接受放疗的患者。中位总剂量、单次剂量和等效剂量 2Gy 分数（EQD2）分别为 45.0Gy、3.0Gy 和 46.0Gy。中位分割次数为 15 次，中位治疗时间为 3 周。10 名患者接受了替莫唑胺治疗。评估了 6 个因素与生存的关系，包括胶质母细胞瘤的位置、卡氏功能状态评分（KPS）、性别、年龄、EQD2 和替莫唑胺。
结果
KPS≥60 显示出生存改善的趋势（p=0.141）。对于包括 EQD2 在内的其他因素，与生存无显著相关性。
结论
KPS≤50 的患者生存预后较差，似乎是短程放疗的良好候选者。对于 KPS 较好的选定患者，可考虑更积极的治疗。
Zotero 插件